

LETTER to the EDITOR

Editorial Process: Submission:08/14/2024 Acceptance:10/28/2024

The Clinical Significance of Viral Vulnerability and Iron Overload in T-cell Acute Lymphoblastic Leukemia

Asian Pac J Cancer Prev, 25 (10), 3339-3340

Dear Editor

Iron is a vital nutrient and an essential element for life, but it can become a double-edged sword when unbalanced [1]. Iron homeostasis plays a crucial role in the pathogenesis of a wide range of cancers, and is found imbalanced in hematological malignancies including T-cell acute lymphoblastic leukemia (T-ALL). In the context of T-ALL, where iron homeostasis is frequently disrupted, the implications reach beyond the confines of oncology. Cancers of blood-forming tissues, such as those of the lymphatic system and bone marrow, are collectively referred to as leukemia and have long been associated with immunosuppression. Some leukemia types are more prevalent in youngsters but most cases of other types of leukemia are in adults [2]. Humans with healthy BMIs have an average concentration of 50–60 mg of iron per kilogram of body weight, or around 3500–4000 mg of iron overall. The hemoglobin of erythrocytes (RBCs) contains a large portion (2300 mg, or 65%) of the iron in the body. The myoglobin of muscle, enzymes, and cytochromes of other tissues each contain around a tenth of the body's total iron (350 mg). Of the remaining iron, roughly 500 mg is located in reticuloendothelial system (RES) macrophages, 200–1000 mg is retained in hepatocytes as ferritin, and 150 mg is found in the bone marrow [3]. Recent findings have suggested a potential link between overloaded iron in T-ALL and increased susceptibility to viral infections, particularly COVID-19. Additionally, studies have uncovered a previously underappreciated factor contributing to this immune dysregulation-iron overload. This research perspective explores the intricate interplay between iron metabolism, T-ALL, and viral infections, shedding light on a novel avenue for investigation and therapeutic intervention. By examining the molecular underpinnings, refining clinical management strategies, and exploring novel therapeutic interventions, we aim to shed light on this intricate interplay for the benefit of T-ALL patients worldwide. Iron overload in T-ALL primarily stems from multiple blood transfusions, ineffective erythropoiesis, and the release of iron from damaged red blood cells [4]. The accumulation of excess iron, primarily in the liver, spleen, and bone marrow, leads to the formation of labile iron pools. These pools of free iron can act as a catalyst for the production of harmful reactive oxygen species (ROS), compromising cellular integrity and immune function. In T-ALL, this vicious cycle exacerbates the already fragile immune

system, increasing susceptibility to infections. Emerging evidence suggests that iron overload in T-ALL patients may create an ideal environment for viral infections to thrive [5]. Viruses, including SARS-CoV-2, the causative agent of COVID-19, exploit the heightened iron levels in host cells for their replication and propagation. Iron overload can augment viral replication, creating a fertile ground for viral spread within the host. Moreover, the compromised immune response in T-ALL patients may further hamper the body's ability to mount an effective defence against viral invaders. A pressing question in this field pertains to the molecular mechanisms by which iron overload in T-ALL patients modulates their susceptibility to viral infections [6]. Investigating the interplay between iron-regulatory proteins, viral replication processes, and immune response pathways could provide critical insights. Cutting-edge technologies like single-cell sequencing and proteomics hold promise for deciphering these intricate molecular networks. Understanding the relationship between iron overload in T-ALL and viral susceptibility opens new doors for therapeutic strategies [7]. Targeting iron metabolism in T-ALL, through iron chelation therapy or erythropoiesis-stimulating agents, may alleviate iron overload and reduce the risk of viral infections. Additionally, vaccination strategies tailored to immunocompromised T-ALL patients may warrant exploration to bolster their defense against viral threats [8]. In the era of precision medicine, we anticipate the development of personalized therapeutic strategies for iron-overloaded T-ALL patients. Targeting iron metabolism with precision, such as through genetically tailored iron chelation agents, could offer a novel avenue for intervention [9]. Moreover, gene editing technologies like CRISPR-Cas9 may potentially restore balanced iron homeostasis in T-ALL cells. Understanding the nexus between iron overload, T-ALL, and viral infections benefits individual patients and has broader public health implications [6]. By elucidating the risk factors and underlying mechanisms, we can refine public health strategies, inform vaccination policies, and develop targeted interventions to protect vulnerable populations during pandemics. The intersection of iron overload in T-ALL and susceptibility to viral infections, including COVID-19, represents a frontier ripe for exploration [10]. Fe-based nanoparticles will continue to get attention because of their multiple advantages. Future research will provide strategic options to increase treatment efficacy by combining iron-based nanoparticles with other

substances that cause ferroptosis, targeting certain small molecules, and/or modifying the expression of certain genes that regulate proteins involved in iron metabolism. Combining efforts from several fields to develop a logical design of efficient T-ALL therapeutic techniques based on iron metabolism seems intriguing [11]. Future research should strive to unravel the intricate molecular mechanisms, refine clinical risk assessment, and pioneer personalized therapeutic approaches. By doing so, we aim to enhance the prognosis, quality of life, and long-term outcomes for T-ALL patients facing the dual challenge of their underlying condition and viral infections. As we embark on this journey of discovery, collaboration among hematologists, virologists, immunologists, and molecular biologists will be paramount. Together, we have the potential to unlock novel insights that will reshape the landscape of T-ALL care and viral infection prevention. This future research perspective outlines key areas of investigation and potential advancements in understanding the relationship between iron overload in T-ALL and susceptibility to viral infections. It underscores the importance of interdisciplinary collaboration and personalized medicine in addressing this complex healthcare challenge.

Author Contribution Statement

RS is the guarantor of the study. RS and SP wrote the first draft, and all contributed to subsequent drafts and the final paper. RS, SP, M, and NH conceived and designed it. All authors reviewed and approved the final draft.

Acknowledgments

First and foremost, I want to express my gratitude to Prof. (Dr.) Ranjana Singh, my mentor, for her essential assistance, encouragement, and direction during this research project. I would also like to thank Prof. Alireza Mosavi Jarrahi and the editorial team for their meticulous editing, which greatly increased the study's lucidity. Insightful feedback and a stimulating academic environment were provided by my friend and colleague Dr. Mohit, who has been supportive throughout. Their encouragement was tremendously motivating during this journey, and their invaluable contributions were crucial in determining the direction of this article.

Conflict of Interest

The authors have no conflict of interest to declare.

References

1. Youssef LA, Spitalnik SL. Iron: A double-edged sword. *Transfusion*. 2017;57(10):2293-7. <https://doi.org/10.1111/trf.14296>.
2. Pandey S, Singh R, Habib N, Singh V, Kushwaha R, Tripathi AK, et al. Expression of cxcl8 (il-8) in the pathogenesis of t-cell acute lymphoblastic leukemia patients. *Cureus*. 2023;15(9):e45929. <https://doi.org/10.7759/cureus.45929>.
3. Yiannikourides A, Latunde-Dada GO. A short review of

iron metabolism and pathophysiology of iron disorders. *Medicines (Basel)*. 2019;6(3). <https://doi.org/10.3390/medicines6030085>.

4. Yokus O, Herek C, Cinli TA, Goze H, Serin I. Iron overload during the treatment of acute leukemia: Pretransplant transfusion experience. *Int J Hematol Oncol*. 2021;10(3):Ijh36. <https://doi.org/10.2217/ijh-2021-0005>.
5. Pandey S, Singh R, Habib N, Tripathi RM, Kushwaha R, Mahdi AA. Regulation of hypoxia dependent reprogramming of cancer metabolism: Role of hif-1 and its potential therapeutic implications in leukemia. *Asian Pac J Cancer Prev*. 2024;25(4):1121-34. <https://doi.org/10.31557/apjcp.2024.25.4.1121>.
6. Weber S, Parmon A, Kurrle N, Schnütgen F, Serve H. The clinical significance of iron overload and iron metabolism in myelodysplastic syndrome and acute myeloid leukemia. *Front Immunol*. 2020;11:627662. <https://doi.org/10.3389/fimmu.2020.627662>.
7. Yassin MA, Soliman A, De Sanctis V, Hmissi SM, Abdulla MAJ, Ekeibed Y, et al. The impact of iron overload in patients with acute leukemia and myelodysplastic syndrome on hepatic and endocrine functions. *Acta Biomed*. 2018;89(3-s):18-22. <https://doi.org/10.23750/abm.v89i3-S.7213>.
8. Rieger CT, Liss B, Mellinshoff S, Buchheidt D, Cornely OA, Egerer G, et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-guideline of the infectious diseases working party (agiho) of the german society for hematology and medical oncology (dgho). *Ann Oncol*. 2018;29(6):1354-65. <https://doi.org/10.1093/annonc/mdy117>.
9. Benadiba J, Rosilio C, Nebout M, Heimeroth V, Neffati Z, Popa A, et al. Iron chelation: An adjuvant therapy to target metabolism, growth and survival of murine pten-deficient t lymphoma and human t lymphoblastic leukemia/lymphoma. *Leuk Lymphoma*. 2017;58(6):1433-45. <https://doi.org/10.1080/10428194.2016.1239257>.
10. Habib HM, Ibrahim S, Zaim A, Ibrahim WH. The role of iron in the pathogenesis of covid-19 and possible treatment with lactoferrin and other iron chelators. *Biomed Pharmacother*. 2021;136:111228. <https://doi.org/10.1016/j.biopha.2021.111228>.
11. Wang F, Lv H, Zhao B, Zhou L, Wang S, Luo J, et al. Iron and leukemia: New insights for future treatments. *J Exp Clin Cancer Res*. 2019;38(1):406. <https://doi.org/10.1186/s13046-019-1397-3>.

Ranjana Singh^{1*}, Sandeep Pandey^{1*}, Mohit², Nimra Habib¹

¹Department of Biochemistry, King George's Medical University, Lucknow, U.P., India. ²Department of Centre for Advanced Research, King George's Medical University, Lucknow, U.P., India. *For Correspondence: ranjanasingh@kgmcindia.edu, sandeepandeykgmu@gmail.com. Ranjana Singh and Sandeep Pandey have equal contributions in this study.